VAL-083, Dianhydrogalactitol

DRUG3 trials

Sponsors

Kintara Therapeutics, Inc., DelMar Pharmaceuticals, Inc.

Conditions

Brain CancerGBMGlioblastomaGlioblastoma MultiformeGliomaOvarian Cancer

Phase 1

A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

WithdrawnNCT03281681

DelMar Pharmaceuticals, Inc.Ovarian Cancer

Start: 2021-03-31End: 2022-09-30Updated: 2019-10-18

Phase 2

Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting

CompletedNCT02717962

Kintara Therapeutics, Inc.Brain Cancer, GBM, Glioblastoma +2

Start: 2017-01-20End: 2024-12-30Updated: 2025-08-29

Phase 3

VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM

TerminatedNCT03149575

DelMar Pharmaceuticals, Inc.Brain Cancer, GBM, Glioblastoma +2

Start: 2017-10-27End: 2019-08-31Updated: 2025-09-04

Related Papers

CTNI-73. ASSESSMENT OF MOLECULAR ALTERATIONS IN NEWLY DIAGNOSED GBM MGMT-UNMETHYLATED PATIENTS TREATED WITH VAL-083

Neuro-Oncology2024-11-01

CTNI-26. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING

Neuro-Oncology2021-11-021 citations

Abstract CT238: Phase 2 study of dianhydrogalactitol (VAL-083) inpatients with MGMT-unmethylated, bevacizumab-naivepatients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting

Cancer Research2021-07-01

CTNI-72. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING

Neuro-Oncology2020-11-01

Abstract 5231: Dianhydrogalactitol (VAL-083) exhibits strong efficacy in GBM tumors with different (epi)genetic background and treatment history

Cancer Research2020-08-153 citations

Abstract CT272: Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent or adjuvant setting

Cancer Research2020-08-151 citations

ACTR-12. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING

Neuro-Oncology2019-11-01

Abstract CT115: Phase II study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve recurrent glioblastoma

Cancer Research2019-07-011 citations

Abstract CT115: Phase II study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve recurrent glioblastoma

Clinical Trials2019-07-01

ACTR-27. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE RECURRENT GLIOBLASTOMA

Neuro-Oncology2018-11-014 citations

Abstract CT167: Phase II study of dianhydrogalactitol (VAL-083) in patients with bevacizumab-naive recurrent glioblastoma, MGMT-unmethylated

Cancer Research2018-07-01

48 Phase 2 studies of dianhydrogalactitol (VAL-083) in patients with glioblastoma, MGMT-unmethylated

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques2018-06-011 citations

ACTR-50. CLINICAL TRIALS WITH DIANHYDROGALACTITOL (VAL-083) IN MGMT-UNMETHYLATED GLIOBLASTOMA

Neuro-Oncology2017-11-01

Abstract CT054: Phase II study of dianhydrogalactitol in patients with <i>MGMT</i>-unmethylated bevacizumab-naive recurrent glioblastoma

Cancer Research2017-07-011 citations

Clinical trials of VAL-083 in patients with chemo-resistant glioblastoma.

Journal of Clinical Oncology2017-05-20

P09.57 Clinical trials of VAL-083 in patients with chemoresistant glioblastoma

Neuro-Oncology2017-04-011 citations